Pandemic onset stalled reduction of benzodiazepine use among older Americans, says study
· Medical Xpressby Columbia University's Mailman School of Public Health
edited by Stephanie Baum, reviewed by Andrew Zinin
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Years of progress in reducing benzodiazepine prescribing among older Americans stalled after the onset of the COVID-19 pandemic, according to a decade-long national study from Columbia University Mailman School of Public Health and Columbia University Irving Medical Center. Although benzodiazepine prescribing declined steadily before 2020 and remained below 2015 levels, those reductions leveled off after the pandemic began. Prescribing increased among adults age 75 or older and among patients receiving medications through long-term care pharmacies. The findings are published in Annals of Internal Medicine.
"Our findings suggest that the COVID-19 pandemic may have disrupted progress in reducing benzodiazepine use among older adults," said Mark Olfson, MD, MPH, professor of epidemiology at Columbia University Mailman School of Public Health. "This is concerning because older adults are especially vulnerable to the medications' adverse effects." Olfson is also a professor of psychiatry at Columbia Vagelos College of Physicians and Surgeons.
Benzodiazepines are commonly prescribed to treat anxiety and insomnia, but are generally recommended only for limited use in older adults because they increase the risk of falls, cognitive impairment, motor vehicle crashes and other serious adverse events. Older adults receiving long-term care are particularly vulnerable because of frailty, multiple chronic conditions and prolonged medication use.
The researchers analyzed IQVIA Longitudinal Prescription Claims from January 2015 through December 2024, representing more than 90% of U.S. retail pharmacy prescriptions and approximately 75% to 80% of long-term care pharmacy dispensing. The study included nearly 25 million adults age 65 and older who filled at least one benzodiazepine prescription during the study period. About two-thirds of patients receiving prescriptions were women.
The researchers suggest several factors may have contributed to the change after 2020, including social isolation, staffing shortages in long-term care facilities, reduced access to behavioral therapies and greater reliance on medications during the pandemic. Previous studies have also documented worsening depression symptoms and greater use of psychotropic medications among nursing home residents during this period.
"Although our study cannot determine what caused prescribing patterns to change after 2020, the findings suggest the importance of continuing medication safety efforts for older adults, particularly those age 75 and older and those receiving long-term care," Olfson said. "Regular medication reviews and greater access to effective non-pharmacologic treatments may help reduce unnecessary benzodiazepine use while ensuring that patients continue to receive appropriate care."
The authors conclude that adults age 75 and older and individuals receiving medications through long-term care pharmacies should remain priority populations for medication safety initiatives. Structured medication reviews, expanded access to non-drug therapies, and quality improvement programs may help sustain reductions in potentially inappropriate benzodiazepine use.
Publication details
Benzodiazepine Prescriptions to Older Adults in the United States, 2015 to 2024, Annals of Internal Medicine (2026). DOI: 10.7326/ANNALS-25-05594
Journal information: Annals of Internal Medicine
Key medical concepts
Clinical categories
PsychiatryGeriatric palliative careHealthy agingClinical pharmacology Provided by Columbia University's Mailman School of Public Health Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Pandemic onset stalled reduction of benzodiazepine use among older Americans, says study (2026, July 6) retrieved 6 July 2026 from https://medicalxpress.com/news/2026-07-pandemic-onset-stalled-reduction-benzodiazepine.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.